Career advice for grad students, tips on breaking into biotech venture capital, insights on timing for starting a biotech startup, drug pricing in the U.S., and beyond.
Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential.
I can connect you with the VP of Comms if you wanted to host them on your pod.
Hey Pulse!
Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential.
I can connect you with the VP of Comms if you wanted to host them on your pod.
https://www.slack-capital.com/p/exozymes-research-report